Joined in 2023 
82 
63 About this deal
There is a need for therapeutic approaches that enable not only suppression of viral replication, but resolution of chronic HBV infection. About GSK3228836 Curative treatments for hepatitis B infections with antiviral agents represent the current focus for Professor Locarnini who is also interested in intellectual property issues when applied to clinical and diagnostic virology. He is a named inventor on over 20 internationally granted patents. Chronic hepatitis B is a major global health problem caused by the hepatitis B virus. It is a long-lasting infection that occurs when the body’s immune system is unable to fight off the virus enabling it to persist in the blood and liver. Current treatment options, which include nucleoside/nucleotide analogues, can suppress but not clear the virus, so need to be taken for life. He worked at the Victorian Infectious Diseases Reference Laboratory (VIDRL, originally Fairfield Hospital Virus Laboratory) from 1989, as Director of Laboratory Services from 1990 to 1998 and, in 1993, he oversaw the amalgamation of all the Fairfield Laboratories into the one service of the VIDRL. He subsequently assumed the position of Head, Research & Molecular Development of VIDRL when the laboratory relocated to Melbourne Health in 1998.
ClearB Therapeutics was co-founded in 2017 with Professor Stephen Locarnini and the Victoria Infectious Diseases Reference Laboratory in Melbourne, Australia. ClearB is working to develop immune based therapies designed to drive functional cure of hepatitis B infection. The work is grounded in proprietary insights derived from studying rare-event infection resolution in patients who suffer from CHB. For more information, please visit https://clearbtherapeutics.com/. As we continue to progress our therapeutic vaccine candidate, CLB-3000, toward first in human trials, we are excited to share our preclinical data with the Hepatitis B community,” said Aileen Rubio, PhD., CEO for the company. “Chronic infection with Hepatitis B (CHB) remains a significant disease, where functional cure has so far been elusive and combination therapies are likely needed. We believe that re-education of patients’ immune systems to break tolerance of their chronic HBV infections through co-administration of ClearB’s therapeutic vaccine could become an important component of such treatment regimens.” GSK is exploring sequential treatment trials of bepirovirsen with other therapeutic modalities, with the aim of increasing functional cure rate in more patients and reducing the overall burden of CHB. These include: We are beyond thrilled to be able to advance our therapeutic vaccine candidate, CLB-3000, toward first in human trials in patients with CHB. We look forward to sharing emerging clinical data with the Hepatitis B community as it becomes available” said Aileen Rubio, PhD, CEO for the company. “CHB infection remains a substantial global health care problem in need of safe and effective therapies. We believe that boosting of patients’ own immune system with ClearB’s therapeutic vaccine, CLB-3000, could become an important component of evolving combination treatment regimens.”
Abstract Title: Impact of various expression systems on efficacy of HBsAg therapeutic vaccines to achieve clearance in a mouse model of chronic hepatitis B For the selected 300mg dose of GSK’836, reductions in HBsAg were observed in NA-treated (HBeAg negative) and NA-naïve patients (HBeAg positive and negative): Across both treatment groups, of the six patients with HBsAg reductions >3.0 log 10 IU/ml, four patients had levels falling below the limit of quantification (0.05 IU/ml). Prolonged HBsAg loss was observed in one-NA treated patient (from Day 36 to Day 113) and one NA-naïve patient (from Day 23 to Day 126).
UK based test Laboratories have completed the latest Gold Standard COVID-19 testing in October 2020, in which our product achieved Log4, resulting in a 99.99% virucidal kill. In the NA-naïve group (n=12), average [SD] reduction reached -1.66 [1.48] log 10 IU/ml vs. placebo 0.00 [0.47], n=6, p<0.001. The B-Clear trial consisted of two parallel cohorts, one for patients receiving NA treatment and the other for patients who were not-on-NA. Patients were randomised into 1 of 4 treatment arms within each cohort, with treatment administered weekly with or without loading doses (LD) on days 4 and 11:
Contact us
The aerosol disinfectant disperses a high-performance disinfectant-Alcohol solution that is suitable for use on all types of surfaces, ideal for areas such as food preparation areas, gyms, offices, homes, trains planes and automobiles. Providing a highly effective sanitisation eradicating the virus even in the hard to get to places. Abstract Title : Therapeutic vaccination with CLB-3000 in a mouse model of chronic Hepatitis B induces anti-HBs responses associated with functional cure Professor Man-Fung Yuen, Principal Investigator and Chief of Division of Gastroenterology and Hepatology, Queen Mary Hospital, The University of Hong Kong, said: “The goal to achieve functional cure at an early age would potentially have a lower risk of liver-related complications and liver cancer. In addition, enhanced immune control associated with functional cure would potentially allow patients to be free of long-term medications. The promising results of this early-phase study warrant further investigation in efforts to achieve this goal.” The end of study results will be presented today at the American Association for the Study of Liver Diseases’ Liver Meeting 2022 (AASLD) in Washington DC, and simultaneously published in the New England Journal of Medicine. Global Hepatitis Report 2017. World Health Organization. https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/ Accessed on November 29, 2019
Great Deal 
New Comment